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Recent studies from the Society of Thoracic Surgeons/
American College of Cardiology Transcatheter
Valve Therapy Registry have reported 30-day and
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rapid uptake of TAVR, little is known about hospital-
level variation in volume and outcomes.
We studied hospital performance on TAVR using
data from all Medicare fee-for-service (FFS) beneﬁ-
ciaries $65 years of age who underwent TAVR from
January 1, 2011, to December 31, 2013, identiﬁed using
International Classiﬁcation of Diseases-Ninth Revi-
sion-Clinical Modiﬁcation procedure codes 35.05 and
35.06. For each hospital that performed at least 1
TAVR during the study period, we calculated
risk-standardized 30-day mortality (30-day risk stan-
dardized mortality rate [RSMR]), 1-year mortality (1-
year RSMR), and 30-day all-cause readmission (30-
day risk standardized readmission rate [RSRR]) us-
ing the Centers for Medicare & Medicaid Services risk-
standardized method (2,3), which employs 2-level
(patient and hospital) hierarchical logistic regression
models that account for the clustering of patients
within the same hospital as well as patient-speciﬁc
information on age and sex and a number of comor-
bidities identiﬁed from secondary discharge diag-
nosis codes in the index hospitalization as well as
principal or secondary diagnosis codes of all inpatient
hospitalizations up to 1 year prior.
To study the effect of the variation in hospital per-
formance on an individual patient’s outcome, we
quantiﬁed the between-hospital variation by ﬁtting a
mixed model at the patient level with hospital random
effects to estimate the odds ratio of death within 30
days for a Medicare FFS patient undergoing TAVR at a
hospital that is 1 SD above the national average 30-day
mortality rate relative to undergoing TAVR at a hos-
pital that is 1 SD below the national average, adjusting
for patient characteristics from the Centers for Medi-
care & Medicaid Services models; we made similar
models for 1-year mortality and 30-day readmission. If
the difference in outcome at a hospital 1 SD above is not
signiﬁcantly different than that at a hospital 1 SD
below, then the odds ratio estimate will cross 1.0.
During 2011 to 2013, 417 hospitals performed a total
of 14,722 TAVR procedures for Medicare FFS beneﬁ-
ciaries. The median (interquartile range [IQR]) num-
ber of TAVRs performed per hospital during the study
period was 17 (2 to 46). The median (IQR) 30-day
RSMR was 6.0% (5.2% to 6.9%) ranging from 3.8% to
10.2%, 1-year RSMR was 17.5% (16.2% to 19.1%) with a
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2679range of 11.8% to 25.6%, and 30-day RSRR was 20.9%
(20.2% to 22.1%) with a range of 17.1% to 24.4%.
The top 7 principal diagnoses for these readmissions
were heart failure (4.8% of all readmissions), post-
operative complications such as shock, hematoma,
wound dehiscence, and infection (1.4%), arrhyth-
mias (1.1%), sepsis (0.9%), pneumonia (0.8%),
gastrointestinal bleed (0.6%), and mechanical device
complications (0.5%). Adjusting for patient charac-
teristics, the odds of each adverse outcome for a pa-
tient treated at a hospital 1 SD above the national
average relative to that of a patient treated at a hos-
pital 1 SD below the national average was statistically
signiﬁcant (Figure 1).
Since the Food and Drug Administration approval
of TAVR in November 2011, there has been rapid
expansion in the number of hospitals performing
TAVR. Our results show marked variation in hospital
performance with TAVR, with an IQR of 1.8% for 30-
day RSMR. For perspective, the IQR for 30-day
RSMR for isolated coronary artery bypass grafting, a
commonly performed invasive cardiac procedure,
is 1% (4).
We found that for an individual patient, the
between-hospital variation translates to a >2-fold
higher risk of dying within 30 days for a patient un-
dergoing TAVR at a hospital 1 SD above the national
average compared with undergoing TAVR at a hos-
pital 1 SD below. The between-hospital variation was
lower for 1-year mortality and 30-day readmission,
but remained substantial. Some of this between-
hospital variation can be attributed to clinical fac-
tors insufﬁciently captured by our adjustment model,
but hospital and system factors are likely also
important drivers of this variation. In addition, TAVR
volume and duration of center experience were
not assessed and could inﬂuence outcomes. As the
importance of hospital and system factors was not
investigated in this paper henceforth, the conclu-
sions of this paper reﬂect the authors’ opinion.
This study serves as an important benchmark
for quality measurement and future performance
improvement efforts for TAVR. Moving forward, as
more centers and operators begin performing TAVR,
and existing centers and operators become more
proﬁcient, it will be important to continue to monitor
the extent of hospital variation to ensure the delivery
of optimal outcomes for patients.Karthik Murugiah, MD
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2015.Effect of Vitamin D
Supplementation on
Aortic Stiffness and
Arterial Hemodynamics
in People With
Osteoarthritis and
Vitamin D DeﬁciencyIncreased aortic stiffness (aPWV), peripheral blood
pressure (pBP), and central hemodynamic parameters
independently predict cardiovascular events and all-
cause mortality (1,2). Moreover, BP variability (BPV)
